4DMT to Participate in Upcoming Investor Conference
4DMT to Participate in Upcoming Investor Conference
EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at an upcoming investor conference in May. Members of the management team will also be available for one-on-one meetings.
加利福尼亞州埃默裏維爾，2024年5月7日（GLOBE NEWSWIRE）——專注於釋放基因藥物治療大型市場疾病的全部潛力的領先臨床階段基因藥物公司4D Molecular Therapeutics（納斯達克股票代碼：FDMT、4DMT或公司）今天宣佈，管理層將參加即將於5月舉行的投資者會議的爐邊談話。管理團隊成員也將參加一對一的會議。
Bank of America Health Care Conference 2024
2024 年美國銀行醫療保健會議
| Presentation Date: | Tuesday, May 14, 2024 |
| Presentation Time: | 3:40 p.m. PT / 6:40 p.m. ET |
| Webcast Link: | Webcast |
| 演示日期： | 2024 年 5 月 14 日，星期二 |
| 演講時間： | 太平洋時間下午 3:40 /美國東部時間下午 6:40 |
| 網絡直播鏈接： | 網絡直播 |
Archived copies of the webcasts will be available for up to one year by visiting the "Investors" section of the 4DMT website at
網絡廣播的存檔副本最多可提供一年，請訪問4DMT網站的 “投資者” 部分，網址爲
About 4DMT
4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT's proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine help us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases in ophthalmology, pulmonology, and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics, 4DMT, 4D, Therapeutic Vector Evolution, and the 4DMT logo are trademarks of 4DMT.
關於 4DMT
4DMT是一家領先的臨床階段基因藥物公司，專注於釋放基因藥物治療眼科和肺科領域大型市場疾病的全部潛力。4DMT的專有發明平台治療載體進化將諾貝爾獎得主定向進化的力量與大約10億個合成AAV衣殼衍生序列相結合，發明了定製和進化的載體，用於我們的全資和合作候選產品。我們的產品設計、開發和製造引擎幫助我們高效地創建和推進多樣化的產品線，目標是徹底改變醫學，爲數百萬患者提供潛在的治療療法。目前，4DMT正在推進五種臨床階段和兩種臨床前候選產品，每種候選產品均針對眼科、肺病學和心臟病學領域的罕見和大型市場疾病量身定製。此外，4DMT還通過基因編輯合作伙伴關係推進中樞神經系統項目。4D Molecular Therapeutics、4DMT、4D、治療載體進化以及4DMT徽標是4DMT的商標。
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
我們所有的候選產品均處於臨床或臨床前開發階段，尚未獲得 FDA 或任何其他監管機構的上市批准。對於我們正在研究的治療用途的候選產品的安全性或有效性，沒有作出任何陳述。
Learn more at and follow us on LinkedIn.
在領英上了解更多信息並關注我們。
Contacts:
聯繫人：
Media:
媒體：
Katherine Smith
Inizio Evoke Comms
Katherine.Smith@inizioevoke.com
凱瑟琳·史密斯
Inizio Evoke Comms
Katherine.Smith@inizioevoke.com
Investors:
投資者：
Julian Pei
Head of Investor Relations and Corporate Communications
Investor.Relations@4DMT.com
朱利安培
投資者關係和企業傳播主管
Investor.Relations@4DMT.com
譯文內容由第三人軟體翻譯。